دورية أكاديمية
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
| العنوان: | Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation. |
|---|---|
| المؤلفون: | Annavarapu S; Comprehensive Health Insights, Louisville, KY 40202, USA., Gandhi PK; Boehringer Ingelheim, Ridgefield, CT 06877, USA., Li Y; Comprehensive Health Insights, Louisville, KY 40202, USA., Arora P; Boehringer Ingelheim, Ridgefield, CT 06877, USA., Moretz C; Comprehensive Health Insights, Louisville, KY 40202, USA., Wang C; Boehringer Ingelheim, Ridgefield, CT 06877, USA., Sander SD; Boehringer Ingelheim, Ridgefield, CT 06877, USA., Andrews GA; Humana Inc., Louisville, KY 40202, USA. |
| المصدر: | Journal of comparative effectiveness research [J Comp Eff Res] 2018 Jul; Vol. 7 (7), pp. 685-691. Date of Electronic Publication: 2018 May 29. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Royston, UK : Becaris Publishing Original Publication: London : Future Medicine |
| مواضيع طبية MeSH: | Anticoagulants/*therapeutic use , Atrial Fibrillation/*drug therapy , Dabigatran/*therapeutic use , Warfarin/*therapeutic use, Aged ; Antithrombins/economics ; Antithrombins/therapeutic use ; Atrial Fibrillation/economics ; Cohort Studies ; Costs and Cost Analysis ; Dabigatran/economics ; Databases, Factual ; Drug Costs ; Female ; Humans ; Male ; Medicare/economics ; Medication Adherence ; Proportional Hazards Models ; Retrospective Studies ; Stroke/economics ; Stroke/prevention & control ; United States ; Warfarin/economics |
| مستخلص: | Factors influencing differences in persistence between dabigatran and warfarin in patients with nonvalvular atrial fibrillation (NVAF) remain unclear. Aim: Compare differences in persistence between new dabigatran and warfarin users in patients newly diagnosed with NVAF, adjusting for sociodemographics, clinical characteristics, patient out-of-pocket cost and other covariates. Methods: A retrospective matched-cohort study was conducted using a US claims database of Medicare and commercially insured patients with NVAF aged≥ 18 years. Persistence and monthly out-of-pocket costs for dabigatran or warfarin were calculated and adjusted for covariates using Cox proportional hazard models. Results & Conclusion: Unadjusted persistence was significantly lower among dabigatran users (n = 1025) compared with matched warfarin users (38 vs 46%). Adjusting for covariates rendered this difference insignificant (hazard ratio = 0.930). |
| فهرسة مساهمة: | Keywords: dabigatran; nonvalvular atrial fibrillation; out of pocket cost; persistence; warfarin |
| المشرفين على المادة: | 0 (Anticoagulants) 0 (Antithrombins) 5Q7ZVV76EI (Warfarin) I0VM4M70GC (Dabigatran) |
| تواريخ الأحداث: | Date Created: 20180530 Date Completed: 20190909 Latest Revision: 20190909 |
| رمز التحديث: | 20231215 |
| DOI: | 10.2217/cer-2017-0081 |
| PMID: | 29808717 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2042-6313 |
|---|---|
| DOI: | 10.2217/cer-2017-0081 |